Prostate Risk and Monitoring During Testosterone Replacement Therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing findings from multiple published randomized trials
PubMed 38753865 · doi:10.1210/clinem/dgae334
What was done
This review examined prospective prostate safety data from randomized controlled trials evaluating testosterone replacement therapy (TRT) versus placebo for one year or longer in men with hypogonadism. It specifically focuses on major trials including the Testosterone Trials, the TEAAM trial, the Testosterone for Diabetes Mellitus trial, and the large-scale TRAVERSE trial.
What was found
No quantitative effect estimates or event counts are reported in the abstract. Qualitatively, in hypogonadal men screened to exclude high baseline prostate cancer risk, the incidence of high-grade prostate cancer, any prostate cancer, acute urinary retention, surgical intervention for benign prostatic hyperplasia, prostate biopsy, and new pharmacotherapy for lower urinary tract symptoms did not differ between testosterone and placebo groups. Testosterone did not worsen lower urinary tract symptoms, but was associated with a greater increase in prostate-specific antigen (PSA) than placebo in the first year.
Why it matters
Synthesizing modern randomized trial data (especially TRAVERSE), this review affirms that testosterone replacement in pre-screened hypogonadal men does not increase short- to medium-term risk of major adverse prostate outcomes.
Limits
The abstract reports no numerical values, effect sizes, or participant counts. The conclusions apply strictly to men pre-screened to exclude baseline high risk of prostate cancer, so they cannot be generalized to unscreened populations. As a narrative review rather than a formal systematic review, synthesis methodology and study selection may introduce bias.
Cited by
- contradicts Scientific data demonstrates that testosterone supports the prostate and can lower the risk of prostate cancer.